A Nobel-winning anti-parasitic that hits tubulin, mitochondria, p53 and HIF-1 in cancer cells, and, combined with a benzimidazole, 'attacks cancer twenty ways.'

Broad preclinical literature across cancer types, including sensitizing lung cancer cells to paclitaxel.

Only human outcome study is uncontrolled, unblinded, self-reported, and authored by the protocol's advocates.

Hulscher, Marik, Makis et al., Anticancer Research 2026;46(6):3243, PMID 42203321, Rockwell et al., JAMA Network Open 2026;9(5):e2616780 (demand study, not efficacy), Sulik et al., Eur J Med Chem Reports 2024, Hayashi et al., Anticancer Research 2024;44(12):5271